GERON CORP Payments to Acquire Marketable Securities
GERON CORP (GERN) reported Payments to Acquire Marketable Securities of $123.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- GERON CORP payments to acquire marketable securities for the quarter ending 2026-06-30 was $88.90M, a 15.91% increase year-over-year.
- GERON CORP payments to acquire marketable securities for the quarter ending 2026-03-31 was $34.52M, a 25.72% decline year-over-year.
- GERON CORP payments to acquire marketable securities for the quarter ending 2025-12-31 was $104.22M, a 43.60% decline year-over-year.
- GERON CORP payments to acquire marketable securities for the quarter ending 2025-09-30 was $77.03M, a 17.05% increase year-over-year.
- GERON CORP payments to acquire marketable securities for fiscal 2025 was $304.42M, a 36.17% decline from fiscal 2024.
- GERON CORP payments to acquire marketable securities for fiscal 2024 was $476.93M, a 0.28% increase from fiscal 2023.
- GERON CORP payments to acquire marketable securities for fiscal 2023 was $475.59M, a 84.33% increase from fiscal 2022.
- GERON CORP payments to acquire marketable securities for fiscal 2022 was $258.01M, a 45.41% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $88.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $123.42M 10-Q · filed 2026-08-05 | $227.64M derived: sum of 3 quarters · filed 2026-08-05 | $304.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $34.52M 10-Q · filed 2026-05-06 | $138.74M derived: sum of 2 quarters · filed 2026-05-06 | $215.77M derived: sum of 3 quarters · filed 2026-05-06 | $292.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $104.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $181.25M derived: sum of 2 quarters · filed 2026-03-02 | $257.94M derived: sum of 3 quarters · filed 2026-08-05 | $304.42M 10-K · filed 2026-03-02 |
| 2025-09-30 | $77.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $153.72M derived: sum of 2 quarters · filed 2026-08-05 | $200.20M 10-Q · filed 2025-11-07 | $384.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $76.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $123.17M 10-Q · filed 2026-08-05 | $307.96M derived: sum of 3 quarters · filed 2026-08-05 | $373.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $46.48M 10-Q · filed 2026-05-06 | $231.27M derived: sum of 2 quarters · filed 2026-05-06 | $297.08M derived: sum of 3 quarters · filed 2026-05-06 | $457.79M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $184.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $250.60M derived: sum of 2 quarters · filed 2026-03-02 | $411.31M derived: sum of 3 quarters · filed 2026-03-02 | $476.93M 10-K · filed 2026-03-02 |
| 2024-09-30 | $65.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $226.52M derived: sum of 2 quarters · filed 2025-11-07 | $292.14M 10-Q · filed 2025-11-07 | $308.01M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $160.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $226.33M 10-Q · filed 2025-08-06 | $242.20M derived: sum of 3 quarters · filed 2026-03-02 | $346.21M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $65.62M 10-Q · filed 2025-05-07 | $81.48M derived: sum of 2 quarters · filed 2026-03-02 | $185.49M derived: sum of 3 quarters · filed 2026-03-02 | $299.60M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $15.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $119.88M derived: sum of 2 quarters · filed 2026-03-02 | $233.98M derived: sum of 3 quarters · filed 2026-03-02 | $475.59M 10-K · filed 2026-03-02 |
| 2023-09-30 | $104.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $218.12M derived: sum of 2 quarters · filed 2024-11-07 | $459.73M 10-Q · filed 2024-11-07 | $620.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $114.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $355.72M 10-Q · filed 2024-08-08 | $516.39M derived: sum of 3 quarters · filed 2025-02-27 | $556.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $241.61M 10-Q · filed 2024-05-02 | $402.28M derived: sum of 2 quarters · filed 2025-02-27 | $442.57M derived: sum of 3 quarters · filed 2025-02-27 | $481.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $160.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $200.96M derived: sum of 2 quarters · filed 2025-02-27 | $239.90M derived: sum of 3 quarters · filed 2025-02-27 | $258.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | $40.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $79.23M derived: sum of 2 quarters · filed 2023-11-02 | $97.34M 10-Q · filed 2023-11-02 | $158.29M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $38.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $57.05M 10-Q · filed 2023-08-03 | $118.00M derived: sum of 3 quarters · filed 2024-02-28 | $152.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $18.10M 10-Q · filed 2023-05-11 | $79.06M derived: sum of 2 quarters · filed 2024-02-28 | $113.11M derived: sum of 3 quarters · filed 2024-02-28 | $170.42M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $60.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $95.00M derived: sum of 2 quarters · filed 2024-02-28 | $152.31M derived: sum of 3 quarters · filed 2024-02-28 | $177.43M 10-K · filed 2024-02-28 |
| 2021-09-30 | $34.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $91.36M derived: sum of 2 quarters · filed 2022-11-07 | $116.48M 10-Q · filed 2022-11-07 | $209.62M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $57.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $82.43M 10-Q · filed 2022-08-11 | $175.56M derived: sum of 3 quarters · filed 2023-03-16 | $213.28M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $25.12M 10-Q · filed 2022-05-09 | $118.26M derived: sum of 2 quarters · filed 2023-03-16 | $155.97M derived: sum of 3 quarters · filed 2023-03-16 | $331.41M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $93.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $130.85M derived: sum of 2 quarters · filed 2023-03-16 | $306.29M derived: sum of 3 quarters · filed 2023-03-16 | $313.20M 10-K · filed 2023-03-16 |
| 2020-09-30 | $37.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $213.15M derived: sum of 2 quarters · filed 2021-11-09 | $220.07M 10-Q · filed 2021-11-09 | $271.26M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $175.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $182.35M 10-Q · filed 2021-08-16 | $233.55M derived: sum of 3 quarters · filed 2022-03-10 | $269.41M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $6.91M 10-Q · filed 2021-05-10 | $58.10M derived: sum of 2 quarters · filed 2022-03-10 | $93.97M derived: sum of 3 quarters · filed 2022-03-10 | $116.29M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $51.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $87.06M derived: sum of 2 quarters · filed 2022-03-10 | $109.38M derived: sum of 3 quarters · filed 2022-03-10 | $153.47M 10-K · filed 2022-03-10 |
| 2019-09-30 | $35.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $58.18M derived: sum of 2 quarters · filed 2020-11-05 | $102.28M 10-Q · filed 2020-11-05 | $140.92M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $22.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $66.41M 10-Q · filed 2020-08-06 | $105.05M derived: sum of 3 quarters · filed 2021-03-11 | $147.71M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $44.09M 10-Q · filed 2020-05-28 | $82.74M derived: sum of 2 quarters · filed 2021-03-11 | $125.39M derived: sum of 3 quarters · filed 2021-03-11 | $212.69M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $38.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $81.30M derived: sum of 2 quarters · filed 2021-03-11 | $168.60M derived: sum of 3 quarters · filed 2021-03-11 | $188.37M 10-K · filed 2021-03-11 |
| 2018-09-30 | $42.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $129.95M derived: sum of 2 quarters · filed 2019-11-06 | $149.72M 10-Q · filed 2019-11-06 | $168.47M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $87.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $107.07M 10-Q · filed 2019-08-01 | $125.81M derived: sum of 3 quarters · filed 2020-03-12 | |
| 2018-03-31 | $19.77M 10-Q · filed 2019-05-02 | $38.51M derived: sum of 2 quarters · filed 2020-03-12 | ||
| 2017-12-31 | $18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $100.01M 10-K · filed 2020-03-12 | ||
| 2017-09-30 | $81.26M 10-Q · filed 2018-11-01 | |||
| 2016-12-31 | $129.25M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |